Read More
C-Path receives EMA’s letter of support to facilitate the diagnoses of type 1 diabetes
The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D) Consortium has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of the proposed regulatory qualification of pancreatic islet autoantibodies commonly used in clinical practice to diagnose T1D: insulin autoantibodies, glutamic acid decarboxylase 65, and insulinoma antigen-2 autoantibodies as enrichment biomarkers for T1D clinical trials.
Read More
>>Hollywood's Exotic Secret For Healthy Weight Loss
Read More
Subscribe to:
Post Comments (Atom)
0 Response to "C-Path receives EMA’s letter of support to facilitate the diagnoses of type 1 diabetes"
Post a Comment